Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

379 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy.
Esfahani K, Buhlaiga N, Thébault P, Lapointe R, Johnson NA, Miller WH Jr. Esfahani K, et al. Among authors: johnson na. N Engl J Med. 2019 Jun 13;380(24):2375-2376. doi: 10.1056/NEJMc1903064. N Engl J Med. 2019. PMID: 31189042 No abstract available.
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH; KEYNOTE-087. Chen R, et al. Among authors: johnson na. J Clin Oncol. 2017 Jul 1;35(19):2125-2132. doi: 10.1200/JCO.2016.72.1316. Epub 2017 Apr 25. J Clin Oncol. 2017. PMID: 28441111 Free PMC article. Clinical Trial.
Systemic cancer therapy: achievements and challenges that lie ahead.
Palumbo MO, Kavan P, Miller WH Jr, Panasci L, Assouline S, Johnson N, Cohen V, Patenaude F, Pollak M, Jagoe RT, Batist G. Palumbo MO, et al. Front Pharmacol. 2013 May 7;4:57. doi: 10.3389/fphar.2013.00057. eCollection 2013. Front Pharmacol. 2013. PMID: 23675348 Free PMC article.
Repression of LKB1 by miR-17∼92 Sensitizes MYC-Dependent Lymphoma to Biguanide Treatment.
Izreig S, Gariepy A, Kaymak I, Bridges HR, Donayo AO, Bridon G, DeCamp LM, Kitchen-Goosen SM, Avizonis D, Sheldon RD, Laister RC, Minden MD, Johnson NA, Duchaine TF, Rudoltz MS, Yoo S, Pollak MN, Williams KS, Jones RG. Izreig S, et al. Among authors: johnson na. Cell Rep Med. 2020 May 19;1(2):100014. doi: 10.1016/j.xcrm.2020.100014. Cell Rep Med. 2020. PMID: 32478334 Free PMC article.
379 results